研究表明微小残留病（MRD）不仅能用于评估ALL患者的疗效、预测复发，还能指导治疗方案的选择 [11,12,13,14]；关于MRD的概念请参见《急性髓系白血病微小残留病检测与临床解读中国 …

2017年11月28日 · Nowadays, minimal residual disease (MRD) is accepted as the strongest independent prognostic factor in acute lymphoblastic leukemia (ALL). It can be detected by …

Currently, the most standardized methods to study MRD in ALL are: multi-parametric flow cytometry (MFC) of leukemia-associated immunophenotypes (LAIP) and, more so, …

2015年6月25日 · Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and …

2021年12月10日 · Evaluation of minimal residual disease (MRD) during first-line treatment and after salvage therapy is part of the standard management of acute lymphoblastic leukemia …

Measurable residual disease (MRD) is the most powerful independent predictor of risk of relapse and long-term survival in adults and children with acute lymphoblastic leukemia (ALL).

Acute lymphoblastic leukemia minimal residual disease (MRD) refers to the presence of residual leukemia cells following the achievement of complete remission, but below the limit of …

Minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) is the presence of post-therapeutic (chemotherapy, immunotherapy, or radiotherapy) leukemia cells within the bone …

2022年5月26日 · In this review, we discuss MRD in ALL, focusing on advantages and limitations between MRD testing techniques and how to monitor MRD in specific patient populations. …

近日于《Blood Advances》发表综述，讨论了支持在成人ALL中使用MRD评估的数据，以及MRD如何合理地为临床决策提供信息，总结为7个临床问题。现整理相关建议供参考。